Monoclonal antibody targeting interleukin-6 achieves sustained reductions in inflammation biomarkers through six months
An investigational monoclonal antibody, pacibekitug, has shown sustained reductions in inflammation-related biomarkers through six months in patients with chronic kidney disease and elevated inflammatory risk associated with heart disease, according to a phase 2 clinical trial called TRANQUILITY. The study, presented at the European Society of Cardiology Congress, found that pacibekitug produced time-averaged reductions in high-sensitivity C-reactive protein (hsCRP) ranging from 76% to 89% compared to a 7% increase in the placebo group.
The long-acting monoclonal antibody targets the interleukin-6 (IL-6) pathway, a signaling protein involved in inflammatory processes associated with cardiovascular risk. The next step is to determine if these biomarker effects translate into improved cardiovascular outcomes in larger studies.
Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
